Terns Pharmaceuticals, Inc. (TERN): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the companies pioneering the next generation of treatments for serious diseases like cancer and obesity? Terns Pharmaceuticals, Inc. (TERN) is one such company, but what exactly is their story, and how do they operate? Join us as we delve into the history, ownership structure, mission, and business model of this clinical-stage biopharmaceutical company, which, as of December 31, 2024, holds $358.2 million in cash and equivalents, extending its financial runway into 2028.

Terns Pharmaceuticals, Inc. (TERN) History

Terns Pharmaceuticals, Inc. Founding Timeline

Year established

Terns Pharmaceuticals was established in 2018.

Original location

The company is headquartered in Foster City, California.

Founding team members

While specific founding team members are not detailed in the provided search results, Terns Pharmaceuticals has been led by a team with experience in global pharmaceutical development and commercialization.

Initial capital/funding

Terns Pharmaceuticals secured an initial funding of $80 million in 2018, led by OrbiMed Asia.

Terns Pharmaceuticals, Inc. Evolution Milestones

Terns Pharmaceuticals, Inc. Transformative Moments

• Focus on NASH and Liver Diseases: A strategic decision to focus on developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases has shaped its pipeline and market positioning.
• Strategic Partnerships and Licensing: The company's ability to form partnerships and license promising drug candidates, such as TERN-101, has been crucial for expanding its portfolio and capabilities.
• Successful Clinical Trial Outcomes: Positive results from clinical trials, particularly for TERN-101 and TERN-201, have validated its scientific approach and attracted investor interest.
• Initial Public Offering (IPO): The company went public in December 2021, raising capital to further advance its clinical programs.

To gain more insights into the investors and stakeholders behind the company, check out this resource: Exploring Terns Pharmaceuticals, Inc. (TERN) Investor Profile: Who’s Buying and Why?

Terns Pharmaceuticals, Inc. (TERN) Ownership Structure

Understanding Terns Pharmaceuticals, Inc.'s (TERN) ownership structure is crucial for investors and stakeholders to assess the balance of power and potential influences on the company's strategic decisions.

TERN's Current Status

Terns Pharmaceuticals, Inc. is a public company, trading under the ticker symbol TERN. This means that a portion of the company is owned by public investors through the stock market, while a significant portion may still be held by institutional investors, company insiders, and early-stage investors.

TERN's Ownership Breakdown

The following table provides an overview of the ownership percentages of Terns Pharmaceuticals, Inc., offering insights into the distribution of shares among various shareholder types.

TERN's Leadership

The leadership team at Terns Pharmaceuticals, Inc. plays a vital role in guiding the company's strategic direction and operational execution. Here are some of the key leaders:

• Weidong Zhong, Ph.D. serves as the Chief Executive Officer and President.
• Martijn Fenaux is the Chief Medical Officer.
• Ann E. Weber, Ph.D. holds the position of Chief Scientific Officer.
• Irina টেtelbaum serves as the Chief Financial Officer.

These individuals, along with other members of the executive team, are responsible for the day-to-day management and long-term strategic planning of Terns Pharmaceuticals, Inc.

To gain further insights into the company's financial performance, you might find this resource helpful: Breaking Down Terns Pharmaceuticals, Inc. (TERN) Financial Health: Key Insights for Investors

Terns Pharmaceuticals, Inc. (TERN) Mission and Values

Terns Pharmaceuticals is dedicated to discovering and developing innovative therapies to treat liver disease, obesity and cancer. The company values scientific rigor, collaboration, and a commitment to improving patient lives.

Terns Pharmaceuticals, Inc. Core Purpose

Official mission statement

Terns Pharmaceuticals' mission statement is to discover, develop, and commercialize innovative therapies to treat liver disease, obesity and cancer.

• Terns Pharmaceuticals focuses on addressing significant unmet medical needs through innovative therapeutic approaches.
• The company is committed to advancing promising drug candidates into clinical development and, ultimately, to patients.

Vision statement

While a specific, publicly declared vision statement for Terns Pharmaceuticals is not readily available, their actions and focus suggest a vision centered on:

• Becoming a leading biopharmaceutical company in the treatment of liver disease, obesity and cancer.
• Developing and delivering transformative medicines that significantly improve patient outcomes.
• Building a sustainable and innovative research and development pipeline.

Company slogan/tagline

Currently, Terns Pharmaceuticals does not have a widely publicized official slogan or tagline. Instead, they emphasize their scientific approach and therapeutic focus. More information about the company's financial standing can be found at: Breaking Down Terns Pharmaceuticals, Inc. (TERN) Financial Health: Key Insights for Investors.

Terns Pharmaceuticals, Inc. (TERN) How It Works

Terns Pharmaceuticals, Inc. (TERN) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative therapies to treat liver diseases, including non-alcoholic steatohepatitis (NASH) and other chronic conditions.

Terns Pharmaceuticals' Product/Service Portfolio

Terns Pharmaceuticals is dedicated to developing treatments for liver diseases. Their pipeline includes several drug candidates targeting different aspects of liver disease pathology.

Terns Pharmaceuticals' Operational Framework

Terns Pharmaceuticals operates through a focused approach to drug development, concentrating on clinical-stage programs that address significant unmet needs in liver disease treatment. Their operational framework includes:

• Drug Development: Terns focuses on advancing its pipeline of drug candidates through rigorous preclinical and clinical trials.
• Clinical Trials: Conducting Phase 1, Phase 2, and Phase 3 clinical trials to evaluate the safety and efficacy of their drug candidates.
• Partnerships and Collaborations: Engaging in strategic partnerships to enhance their research and development capabilities.
• Regulatory Approval: Pursuing regulatory approvals from agencies such as the FDA to bring their therapies to market.

To further understand Terns Pharmaceuticals, Inc. (TERN) consider reading more about Mission Statement, Vision, & Core Values of Terns Pharmaceuticals, Inc. (TERN).

Terns Pharmaceuticals' Strategic Advantages

Terns Pharmaceuticals has several strategic advantages that position it for success in the competitive biopharmaceutical industry:

• Focused Pipeline: A concentrated focus on liver diseases allows for specialized expertise and efficient resource allocation.
• Innovative Drug Candidates: Development of novel therapies targeting key pathways in liver disease pathology.
• Experienced Management Team: A team with a proven track record in drug development and commercialization.
• Strong Financial Backing: Access to capital markets and strategic investors to fund their research and development programs. For example, Terns Pharmaceuticals, Inc. reported a cash balance of $178.1 million as of December 31, 2023, compared to $123.3 million as of December 31, 2022.

Terns Pharmaceuticals, Inc. (TERN) How It Makes Money

Terns Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, generating revenue primarily through the development and potential commercialization of novel therapies for the treatment of liver diseases, including non-alcoholic steatohepatitis (NASH) and other chronic ailments.

Terns Pharmaceuticals, Inc. Revenue Breakdown

As a clinical-stage biopharmaceutical company, Terns Pharmaceuticals currently does not generate revenue from product sales. Its revenue streams are primarily dependent on strategic collaborations, licensing agreements, and milestone payments associated with the progress of its drug development programs.

Terns Pharmaceuticals, Inc. Business Economics

The economic model of Terns Pharmaceuticals is rooted in the high-risk, high-reward nature of pharmaceutical development. Key aspects of their business economics include:

• R&D Investment: Significant capital is allocated to research and development, encompassing drug discovery, preclinical studies, and clinical trials.
• Intellectual Property: Securing and maintaining patents for their drug candidates is crucial for protecting market exclusivity and future revenue streams.
• Partnerships: Collaborations with other pharmaceutical companies can provide financial support, expertise, and resources for drug development and commercialization.
• Regulatory Approval: Successfully navigating the regulatory approval process with agencies like the FDA is essential for bringing products to market.

For insights into the company's guiding principles, you can explore: Mission Statement, Vision, & Core Values of Terns Pharmaceuticals, Inc. (TERN).

Terns Pharmaceuticals, Inc. Financial Performance

As a clinical-stage company, Terns Pharmaceuticals' financial performance is primarily evaluated on its ability to raise capital, manage expenses, and advance its drug pipeline. Key financial metrics include:

• Cash Runway: Monitoring cash reserves and burn rate is vital to ensure sufficient funding for ongoing operations and clinical trials.
• R&D Expenses: Tracking research and development expenditures provides insights into the company's investment in its drug programs.
• Net Loss: As is typical for development-stage biopharmaceutical companies, Terns Pharmaceuticals is expected to report net losses as it invests heavily in R&D.
• Financing Activities: The company's ability to secure funding through equity offerings, debt financing, or strategic partnerships is critical for sustaining its operations.

Terns Pharmaceuticals, Inc. (TERN) Market Position & Future Outlook

Terns Pharmaceuticals is strategically positioned to capitalize on the growing demand for innovative treatments in liver disease and obesity, holding promise for future growth. Mission Statement, Vision, & Core Values of Terns Pharmaceuticals, Inc. (TERN).

Competitive Landscape

Opportunities & Challenges

Industry Position

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on developing innovative therapies for chronic liver diseases and obesity. Its industry position can be further elaborated by:

• Pipeline Diversity: Terns has a diverse pipeline with multiple clinical-stage assets targeting different mechanisms in NASH and obesity.
• Strategic Focus: The company's strategic focus on NASH and obesity, areas with significant unmet medical needs, positions it well for potential growth.
• Innovation: Terns is focused on developing differentiated therapies with novel mechanisms of action, which could provide advantages over existing treatments.